<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H4502B3608B4A496C94D071AA62819FA3" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 2589 IH: Huntington’s Disease Parity Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-05-22</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 2589</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170522">May 22, 2017</action-date><action-desc><sponsor name-id="K000378">Mr. Kinzinger</sponsor> (for himself, <cosponsor name-id="P000096">Mr. Pascrell</cosponsor>, <cosponsor name-id="F000460">Mr. Farenthold</cosponsor>, <cosponsor name-id="T000470">Mr. Tipton</cosponsor>, <cosponsor name-id="P000597">Ms. Pingree</cosponsor>, <cosponsor name-id="C001049">Mr. Clay</cosponsor>, <cosponsor name-id="B001278">Ms. Bonamici</cosponsor>, <cosponsor name-id="D000617">Ms. DelBene</cosponsor>, <cosponsor name-id="R000486">Ms. Roybal-Allard</cosponsor>, <cosponsor name-id="N000179">Mrs. Napolitano</cosponsor>, <cosponsor name-id="C000714">Mr. Conyers</cosponsor>, <cosponsor name-id="M000312">Mr. McGovern</cosponsor>, <cosponsor name-id="L000563">Mr. Lipinski</cosponsor>, <cosponsor name-id="C001067">Ms. Clarke of New York</cosponsor>, <cosponsor name-id="S000250">Mr. Sessions</cosponsor>, <cosponsor name-id="H001045">Mr. Harper</cosponsor>, <cosponsor name-id="K000188">Mr. Kind</cosponsor>, <cosponsor name-id="M001180">Mr. McKinley</cosponsor>, <cosponsor name-id="H001064">Mr. Heck</cosponsor>, <cosponsor name-id="S001192">Mr. Stewart</cosponsor>, <cosponsor name-id="Y000062">Mr. Yarmuth</cosponsor>, <cosponsor name-id="S001150">Mr. Schiff</cosponsor>, <cosponsor name-id="T000463">Mr. Turner</cosponsor>, <cosponsor name-id="K000362">Mr. King of Iowa</cosponsor>, <cosponsor name-id="R000577">Mr. Ryan of Ohio</cosponsor>, <cosponsor name-id="R000395">Mr. Rogers of Kentucky</cosponsor>, <cosponsor name-id="S001170">Ms. Shea-Porter</cosponsor>, <cosponsor name-id="T000472">Mr. Takano</cosponsor>, <cosponsor name-id="G000559">Mr. Garamendi</cosponsor>, <cosponsor name-id="D000610">Mr. Deutch</cosponsor>, <cosponsor name-id="T000193">Mr. Thompson of Mississippi</cosponsor>, <cosponsor name-id="D000619">Mr. Rodney Davis of Illinois</cosponsor>, <cosponsor name-id="L000287">Mr. Lewis of Georgia</cosponsor>, <cosponsor name-id="D000216">Ms. DeLauro</cosponsor>, <cosponsor name-id="F000454">Mr. Foster</cosponsor>, <cosponsor name-id="M001196">Mr. Moulton</cosponsor>, <cosponsor name-id="Y000063">Mr. Yoder</cosponsor>, <cosponsor name-id="D000620">Mr. Delaney</cosponsor>, <cosponsor name-id="H001072">Mr. Hill</cosponsor>, <cosponsor name-id="L000559">Mr. Langevin</cosponsor>, <cosponsor name-id="M001160">Ms. Moore</cosponsor>, <cosponsor name-id="R000583">Mr. Thomas J. Rooney of Florida</cosponsor>, <cosponsor name-id="S001157">Mr. David Scott of Georgia</cosponsor>, <cosponsor name-id="F000461">Mr. Flores</cosponsor>, <cosponsor name-id="Y000033">Mr. Young of Alaska</cosponsor>, <cosponsor name-id="M001143">Ms. McCollum</cosponsor>, <cosponsor name-id="B001243">Mrs. Blackburn</cosponsor>, <cosponsor name-id="R000435">Ms. Ros-Lehtinen</cosponsor>, <cosponsor name-id="J000288">Mr. Johnson of Georgia</cosponsor>, and <cosponsor name-id="S000480">Ms. Slaughter</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To waive the 24-month waiting period for Medicare eligibility for individuals disabled by
			 Huntington’s disease.</official-title></form>
	<legis-body id="HEB7B8C6A199B42E988AB276DDF6B64DC" style="OLC">
 <section id="H41598167B8184A049CF4C25FED64F60E" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Huntington’s Disease Parity Act of 2017</short-title></quote>.</text> </section><section id="H6D877697C7A94A7894C12022673ADD4F"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress makes the following findings:</text>
 <paragraph id="H2356C007BE234094B5F026FE9F9C663E"><enum>(1)</enum><text>Huntington’s disease is a progressive degenerative neurological disease that causes total physical and mental deterioration. In the United States, approximately 30,000 individuals are affected by Huntington’s disease, along with another 200,000 individuals who are genetically <quote>at risk</quote>. There is no effective treatment in terms of halting or slowing the progression of the disease.</text>
 </paragraph><paragraph id="H24D6435F79E2430ABD7B1B3834D80908"><enum>(2)</enum><text>Clinical indicators of Huntington’s disease include—</text> <subparagraph id="H973F9DDF987F4EA695D4DA109A1BE370"><enum>(A)</enum><text>loss of ability to control bodily movements;</text>
 </subparagraph><subparagraph id="HC4A25806872A4E0889F65E582793AA63"><enum>(B)</enum><text>loss of ability to think or act quickly, inability to learn new material, and loss of memory; and</text> </subparagraph><subparagraph id="H9F5C870F7A4742FE9E75D8E541B0D90E"><enum>(C)</enum><text>behavioral or psychological problems, including personality changes, irritability, mood swings, anxiety, obsessive-compulsive behavior, inability to concentrate, decreased motivation, and severe depression.</text>
 </subparagraph></paragraph><paragraph id="H36B6F9DE5003483990141E9C1F40F647"><enum>(3)</enum><text>Adult-onset Huntington’s disease typically results in the development of symptoms in individuals between 30 and 50 years of age. Late-onset Huntington’s disease is characterized by development of symptoms after 50 years of age and is usually associated with a milder course of the disease. Juvenile Huntington’s disease affects individuals who have yet to attain 19 years of age and progresses at a more rapid rate.</text>
 </paragraph><paragraph id="HF3A6D3F732EF42B08E9614001628F821"><enum>(4)</enum><text>Because of the incapacitating nature of Huntington’s disease, individuals living with this illness, including those in the early stages of the disease, are unable to retain employment. As a result, many such individuals rely solely on Social Security Disability Insurance.</text>
 </paragraph><paragraph id="HD8C534A3052D4C018EDDE1182A76493D"><enum>(5)</enum><text>After qualifying for Social Security Disability Insurance, individuals with Huntington’s disease must wait another 24 months before receiving benefits under the Medicare program, despite the fact that such individuals often become incapacitated before reaching the age-eligibility requirement under the Medicare program of 65 years of age.</text>
 </paragraph><paragraph id="H32A59C862C8042CB8F4B039D672E8F62"><enum>(6)</enum><text>In 2000, the Centers for Medicare &amp; Medicaid Services waived the 24-month waiting period requirement for people disabled by amyotrophic lateral sclerosis (<quote>ALS</quote>), a degenerative neurological condition that is similar to Huntington’s disease.</text>
 </paragraph><paragraph id="HFCFF816F7A6C45B8B062F0E428BA3DF0"><enum>(7)</enum><text>In light of the significant cognitive, behavioral, and physical incapacitation faced by individuals with this disease, there is an urgent need for the removal of the 24-month waiting period for coverage under the Medicare program for such individuals, similar to the existing exemption for individuals who have been diagnosed with ALS.</text>
			</paragraph></section><section id="H252F8850C3BA49B4A9F95B5FDF77B6B5"><enum>3.</enum><header>Waiver of 24-month waiting period for coverage under medicare program for individuals diagnosed
			 with Huntington’s disease</header>
 <subsection id="HF14156B1EEDE4EED81E84F78B3121B37"><enum>(a)</enum><header>In general</header><text>Section 226(h) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/426">42 U.S.C. 426(h)</external-xref>) is amended, in the matter preceding paragraph (1), by inserting <quote>or Huntington’s disease (HD)</quote> after <quote>amyotrophic lateral sclerosis (ALS)</quote>.</text>
 </subsection><subsection id="HBB60A6927D214FC1BC1A04E069716F77"><enum>(b)</enum><header>Effective date</header><text>The amendment made by subsection (a) shall apply to benefits under title XVIII of the Social Security Act with respect to items and services furnished in months beginning after the date of the enactment of this Act.</text>
			</subsection></section></legis-body></bill>


